Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?

被引：0
|
作者：
Salazar, Juliana [1 ,2 ]
Moya, Patricia [3 ,4 ]
Altes, Albert [5 ]
Diaz-Torne, Cesar [3 ]
Casademont, Jordi [3 ]
Cerda-Gabaroi, Dacia [6 ]
Corominas, Hector [6 ]
Baiget, Montserrat [1 ,2 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Dept Genet, Barcelona 08025, Spain
[2] CIBERER, U705, Barcelona, Spain
[3] Hosp Santa Creu & Sant Pau, Internal Med Dept, Barcelona 08025, Spain
[4] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
[5] Fundacio Althaia, Hematol Dept, Barcelona, Spain
[6] Hosp Moises Broggi, Rheumatol Dept, Barcelona, Spain
来源：
PHARMACOGENOMICS | 2014年 / 15卷 / 08期
关键词：
5-aminoimidazole-4-carboxamide ribonucleotide transformylase; 5,10-methylenetetrahydrofolate reductase; ATIC; DHFR; dihydrofolate reductase; methotrexate; MTHFR; rheumatoid arthritis; CLINICAL PHARMACOGENETIC MODEL; FUNCTIONAL-ANALYSIS; EFFICACY; RECOMMENDATIONS; MONOTHERAPY; MANAGEMENT; TOXICITY; PREDICT;
D O I：
10.2217/PGS.14.67
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: Methotrexate (MTX) is the first-line treatment option for newly diagnosed rheumatoid arthritis (RA) patients. However, 50-70% of the patients respond to treatment and 30% suffer toxicity. Aim: To identify pharmacogenetic markers of outcome in RA patients treated with MTX. Patients & methods: We analyzed 27 genetic variants in DHFR, TYMS, MTHFR, ATIC and CCND1 genes. Results: We included 124 RA patients treated with MTX monotherapy. In multivariate analyses two variants in the MTHFR gene were associated with response, rs17421511 (p = 0.024) and rs1476413 (p = 0.0086), as well as one in the DHFR gene, rs1643650 (p = 0.026). The ATIC rs16853826 variant was associated with toxicity (p = 0.039). Conclusion: MTHFR, DHFR and ATIC genetic variants can be considered as pharmacogenetic markers of outcome in RA patients under MTX monotherapy.
引用
收藏
页码：1079 / 1090
页数：12
相关论文
共 50 条
  • [41] Polymorphisms for the Clinical Efficacy and Toxicity of Methotrexate in Patients with Rheumatoid Arthritis: Systemic Review
    Alharthi, Ahlam
    Magadmi, Rania
    Jamal, Maha
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2024, 20 (04) : 547 - 551
  • [42] TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis
    Bae, Sang-Cheol
    Lee, Young Ho
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2018, 77 (09): : 824 - 832
  • [43] Effect of thymidylate synthase (TYMS) gene polymorphisms with methotrexate treatment outcome in south Indian Tamil patients with rheumatoid arthritis
    Muralidharan, Niveditha
    Misra, Durga P.
    Jain, Vikramraj K.
    Negi, Vir Singh
    CLINICAL RHEUMATOLOGY, 2017, 36 (06) : 1253 - 1259
  • [44] Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate
    Stamp, Lisa K.
    Chapman, Peter T.
    O'Donnell, John L.
    Zhang, Mei
    James, Jill
    Frampton, Christopher
    Barclay, Murray L.
    Kennedy, Martin A.
    Roberts, Rebecca L.
    PHARMACOGENETICS AND GENOMICS, 2010, 20 (06): : 367 - 376
  • [45] Effect of thymidylate synthase (TYMS) gene polymorphisms with methotrexate treatment outcome in south Indian Tamil patients with rheumatoid arthritis
    Niveditha Muralidharan
    Durga P. Misra
    Vikramraj K. Jain
    Vir Singh Negi
    Clinical Rheumatology, 2017, 36 : 1253 - 1259
  • [46] Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis
    Hayashi, H.
    Fujimaki, C.
    Daimon, T.
    Tsuboi, S.
    Matsuyama, T.
    Itoh, K.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2009, 34 (03) : 355 - 361
  • [47] Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis
    Kumagai, K
    Hiyama, K
    Oyama, T
    Maeda, H
    Kohno, N
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2003, 11 (05) : 593 - 600
  • [48] Regulation of Folate Pathway Related Genes in Methotrexate Naive and Methotrexate Treated Patients with Rheumatoid Arthritis
    Blits, M.
    Jansen, G.
    Assaraf, Y. G.
    Lems, W. F.
    Nurmohamed, M. T.
    van Schaardenburg, D.
    Voskuyl, A. E.
    Wolbink, G. J.
    Vosslamber, S.
    Verweij, C. L.
    JOURNAL OF PATHOLOGY, 2013, 229 : S14 - S14
  • [49] A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate
    Hobl, E. -L.
    Jilma, B.
    Erlacher, L.
    Duhm, B.
    Mustak, M.
    Broell, H.
    Hoegger, P.
    Rizovski, B.
    Mader, R. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (02) : 156 - 163
  • [50] Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes
    Wessels, JAM
    de Vries-Bouwstra, JK
    Heijmans, BT
    Slagboom, PE
    Goekoop-Ruiterman, YPM
    Allaart, CF
    Kerstens, PJSM
    van Zeben, D
    Breedveld, FC
    Dijkmans, BAC
    Huizinga, TWJ
    Guchelaar, HJ
    ARTHRITIS AND RHEUMATISM, 2006, 54 (04): : 1087 - 1095
12345